ScripPatients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with
ScripCasualties Of Risk-Off My time in the City included the management of four UK-listed biotech investment trusts and unit trusts. Investment trusts date back to the mid-1800s and can invest in both priv
ScripBiogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on Ju
ScripWelsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in